Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06414148
Title MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (EpLCART)
Acronym EpLCART
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Peter MacCallum Cancer Centre, Australia
Indications
Therapies
Age Groups: adult | senior
Covered Countries AUS


No variant requirements are available.